Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SNDX
SYNDAX PHARMACEUTICALS, INC.
NASDAQ
$19.54
▼ DOWN 3.08% (-0.62)

KEY STATISTICS

Market Cap$1.73 B
52w High$25.59
52w Low$12.99
Dividend Yield—
Frequency—
P/E-7.78
Volume1.04M
Shares Out.88.61M

COMPANY

LEADERSHIP

Michael A. Metzger
CHIEF EXECUTIVE
Michael A. Metzger

COMPENSATION 2026

Salary$754,300
Stock Awards$2,021,965
Incentive Plan Pay$848,588
All Other Comp.$10,000
Total$7,089,213

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 2, 2016
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
298

PRICE TARGET

Target High$46.00
Target Low$31.00
Target Median$37.00
Target Consensus$37.00

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.$82.79M
NOV
2
MON

PRICE

$19.54 ▼ DOWN 3.08% (−$0.62)
$19.60$19.80$20.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM19.54

About Syndax Pharmaceuticals, Inc.

https://www.syndax.com ↗

Syndax Pharmaceuticals is a clinical-stage biopharma developing cancer therapies, including SNDX-5613 for leukemia and axatilimab for cGVHD, with collaborations and a focus on innovative treatments.

INDUSTRY

Biotechnology

A PRODUCT SYNDAX PHARMACEUTICALS, INC. IS KNOWN FOR

Revuforj (revumenib)
Revuforj (revumenib)

Revuforj is a first-in-class oral menin inhibitor approved by the FDA in 2024 and 2025 for specific relapsed or refractory acute leukemia subtypes, driving the company's recent revenue growth.

COMPETITORS

COMPETITOR
ABBV COMPARE
BMEA COMPARE
GILD COMPARE
JNJ COMPARE
KURA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$32.01M — $48.92M ▲$54.7M ▲
Collaboration revenue$13.86M $19.14M ▲$15.94M ▼$18.09M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
133
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
0.63% · 3.8M
VTS.AX
0.00% · 2.8M
IWM
0.06% · 2.3M
SCHA
0.04% · 422.4K
FYC
0.36% · 255.7K
BR
BRES
0.39% · 137.5K
LABU
0.43% · 136.4K
PRFZ
0.06% · 84.6K
XRSG.L
0.06% · 81.5K
BBP
1.36% · 80.2K
CANC
0.51% · 55.0K
RSSL
0.06% · 42.5K
FHLC
0.02% · 40.6K
ISMD
0.18% · 31.4K
BBSC
0.06% · 24.2K
GSSC
0.04% · 22.6K
SGRW
0.87% · 12.7K
TILT
0.01% · 6.6K
ETLZ.DE
0.05% · 5.3K
RFLR
0.09% · 4.2K
URTY
0.02% · 3.6K
ESSC
0.11% · 2.1K
VETS
0.13% · 1.9K
PINK
0.00% · 846
USFMDN.MX
0.00% · 435
AVUQ
0.00% · 204

INSTITUTIONAL OWNERSHIP

SHARES OWNED
74.41%
HOLDERS
339
TOP 12 OF 339 · RANKED BY POSITION SIZE
Blackrock, Inc.
9.0M sh · $197.18M
Kynam Capital Management, LP
8.5M sh · $131.08M
Blackrock Inc.
7.9M sh · $162.33M
Vanguard Group Inc
6.2M sh · $130.9M
Goldman Sachs Group Inc
5.9M sh · $128.13M
State Street Corp
5.7M sh · $123.69M
Point72 Asset Management, L.P.
4.9M sh · $102.57M
Bank Of America Corp /De/
4.7M sh · $98.97M
Deerfield Management Company, L.P. (Series C)
3.8M sh · $88.3M
Eversept Partners, LP
3.5M sh · $53.34M
Adage Capital Partners Gp, L.L.C.
3.3M sh · $50.95M
Geode Capital Management, LLC
2.6M sh · $56.5M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Metzger Michael A
Purchase · 32.4K shares
2026-07-08
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Metzger Michael A
Purchase · 32.4K shares
2026-07-08
★
OFFICER: HEAD OF R&D, CMO
Botwood Nicholas A.J.
Purchase · 22.5K shares
2026-06-11
★
OFFICER: HEAD OF R&D, CMO
Botwood Nicholas A.J.
Purchase · 31.2K shares
2026-06-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OVERWEIGHT 2
OUTPERFORM 1
8 GRADES IN THE LAST 12 MONTHS
UBS BUY JP Morgan OVERWEIGHT HC Wainwright & Co. BUY Barclays OVERWEIGHT Goldman Sachs BUY Mizuho OUTPERFORM Citigroup BUY BTIG BUY

SECTORS PEERS

PEERPRICE
RLAY$18.77COMPARE
AMLX$34.74COMPARE
ATAI$7.29COMPARE
NKTR$72.52COMPARE
ZBIO$31.27COMPARE
INBX$123.41COMPARE
ORIC$13.24COMPARE
IMTX$9.45COMPARE